Can Zydus Cadila’s COVID-19 Vaccine Win First Pediatric Approval In India?
Saroglitazar PBC Filing By Early 2024
Unless Pfizer or Moderna beat the company to it, Zydus Cadila’s COVID-19 vaccine candidate could be India’s first such jab approved for children. With superior thermostability and proposed economical pricing, it will be one to watch, though a three-dose regimen could be a dampener. Meanwhile, saroglitazar sees slow progress.
You may also be interested in...
A recent study says a cohort of unvaccinated individuals aged under 16 years in Israel showed a nearly two-fold decrease in COVID-19 positivity for each 20 percentage points of individuals vaccinated overall. As Pfizer, Moderna and Bharat Biotech develop pediatric vaccines, should they consider if herd immunity might make such vaccines redundant?
In this week's podcast edition of Five Must-Know Things: a pioneering KRAS inhibitor approval; Organon’s CEO on the company’s plans; Astellas’s mid-term ambitions; trial disappointment for Novartis’s Beovu; and Indian plans for a pediatric COVID vaccine.
Zydus Cadila’s launch of the world’s first biosimilar to Roche’s breast cancer drug Kadcyla in India at an 80% discount to the original's listed price is expected to improve access, and follows its pioneering launch of an adalimumab biosimilar and a NASH therapy